サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1541182

乳がんリキッドバイオプシー市場レポート：製品サービス、循環バイオマーカー、エンドユーザー、地域別、2024年～2032年

Breast Cancer Liquid Biopsy Market Report by Product Services, Circulating Biomarker (Circulating Tumor Cells, Cell-Free DNA, Extracellular Vesicles, and Others), End User, and Region 2024-2032

出版日
発行
IMARC
ページ情報
英文 142 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=143.57円
乳がんリキッドバイオプシー市場レポート：製品サービス、循環バイオマーカー、エンドユーザー、地域別、2024年～2032年
出版日: 2024年08月10日
発行: IMARC
ページ情報: 英文 142 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

乳がんリキッドバイオプシー市場の世界市場規模は2023年に1億3,040万米ドルに達しました。今後、IMARC Groupは、市場は2032年までに4億9,720万米ドルに達し、2024年から2032年の間に15.5％の成長率（CAGR）を示すと予測しています。

乳がんリキッドバイオプシーとは、腫瘍マーカーを同定するためのサンプルとして血液を利用する非侵襲的な医療手順を指します。乳がん疾患の進行度を評価し、上皮成長因子受容体（EGFR）遺伝子変異を検出することで、臨床医が適切な時期に最善の治療方針を選択するのに役立ちます。このプロセスで使用される一般的なバイオマーカーには、循環腫瘍細胞（CTC）、細胞外小胞、循環腫瘍DNAなどがあります。乳がんリキッドバイオプシーには、最小限の侵襲性、新たな病変の特徴づけ、がん治療のための薬剤や治療標的の同定など、いくつかの利点があります。

乳がんリキッドバイオプシー市場傾向：

乳がんの有病率の増加と非侵襲的医療処置への需要の高まりが、主に世界の乳がんリキッドバイオプシー市場を牽引しています。これに加えて、迅速な結果、低コスト、最小限の健康リスク、非侵襲性など、リキッドバイオプシー技術に関連する多くの特典に対する消費者の意識の高まりも市場成長を増強しています。さらに、さまざまな世界的組織が、乳房の健康とがん診断対策について個人を教育する啓発キャンペーンを実施しています。このことは、乳がん生検やその他の関連医療処置に対する政府や民間の償還政策の増加と相まって、市場に明るい見通しをもたらしています。これとは別に、多数のメーカーが、予後の予測、再発の早期診断、連続サンプリング、病気の進行や治療に対する反応性の効率的な長期的モニタリングなど、乳がん管理のいくつかの側面の強化を可能にする高度な生検技術のイントロダクション多額の投資を行っています。さらに、個別化治療の新たな動向と、がん検出のためのポリメラーゼ連鎖反応（PCR）および次世代シーケンシング（NGS）の広範な採用が相まって、今後数年間も世界の乳がんリキッドバイオプシー市場を牽引していくと思われます。

本レポートで扱う主な質問

  • 2023年の世界の乳がんリキッドバイオプシー市場の市場規模は？
  • 2024年～2032年における乳がんリキッドバイオプシー市場の世界市場成長率は？
  • 世界の乳がんリキッドバイオプシー市場に対するCOVID-19の影響は？
  • 世界の乳がんリキッドバイオプシー市場を牽引する主要因は何か？
  • 世界の乳がんリキッドバイオプシー市場の製品サービス別内訳は？
  • 乳がんリキッドバイオプシー市場の世界における主要地域は？
  • 世界の乳がんリキッドバイオプシー市場における主要プレイヤー／企業は？

目次

第1章 序文

第2章 調査範囲と調査手法

  • 調査の目的
  • ステークホルダー
  • データソース
    • 一次情報
    • 二次情報
  • 市場推定
    • ボトムアップアプローチ
    • トップダウンアプローチ
  • 調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

  • 概要
  • 主要業界動向

第5章 世界の乳がんリキッドバイオプシー市場

  • 市場概要
  • 市場実績
  • COVID-19の影響
  • 市場予測

第6章 市場内訳：製品サービス別

  • 試薬キット
    • 市場動向
    • 市場予測
  • 機器
    • 市場動向
    • 市場予測
  • サービス
    • 市場動向
    • 市場予測

第7章 市場内訳：循環バイオマーカー別

  • 循環腫瘍細胞（CTC）
    • 市場動向
    • 市場予測
  • 遊離DNA（cfDNA）
    • 市場動向
    • 市場予測
  • 細胞外小胞（EV）
    • 市場動向
    • 市場予測
  • その他
    • 市場動向
    • 市場予測

第8章 市場内訳：エンドユーザー別

  • リファレンスラボ
    • 市場動向
    • 市場予測
  • 病院および医師のラボ
    • 市場動向
    • 市場予測
  • その他
    • 市場動向
    • 市場予測

第9章 市場内訳：地域別

  • 北米
    • 米国
    • カナダ
  • アジア太平洋地域
    • 中国
    • 日本
    • インド
    • 韓国
    • オーストラリア
    • インドネシア
    • その他
  • 欧州
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • スペイン
    • ロシア
    • その他
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • その他
  • 中東・アフリカ
    • 市場動向
    • 市場内訳：国別
    • 市場予測

第10章 SWOT分析

  • 概要
  • 強み
  • 弱み
  • 機会
  • 脅威

第11章 バリューチェーン分析

第12章 ポーターのファイブフォース分析

  • 概要
  • 買い手の交渉力
  • 供給企業の交渉力
  • 競合の程度
  • 新規参入業者の脅威
  • 代替品の脅威

第13章 価格分析

第14章 競合情勢

  • 市場構造
  • 主要企業
  • 主要企業のプロファイル
    • Biocept Inc.
    • Bio-Rad Laboratories Inc.
    • F. Hoffmann-La Roche AG
    • Fluxion Biosciences Inc.
    • Guardant Health Inc.
    • Illumina Inc.
    • Menarini Silicon Biosystems（The Menarini Group）
    • NeoGenomics Laboratories Inc.
    • Qiagen
    • Sysmex Europe SE（Sysmex Corporation）
図表

List of Figures

  • Figure 1: Global: Breast Cancer Liquid Biopsy Market: Major Drivers and Challenges
  • Figure 2: Global: Breast Cancer Liquid Biopsy Market: Sales Value (in Million US$), 2018-2023
  • Figure 3: Global: Breast Cancer Liquid Biopsy Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 4: Global: Breast Cancer Liquid Biopsy Market: Breakup by Product Services (in %), 2023
  • Figure 5: Global: Breast Cancer Liquid Biopsy Market: Breakup by Circulating Biomarker (in %), 2023
  • Figure 6: Global: Breast Cancer Liquid Biopsy Market: Breakup by End User (in %), 2023
  • Figure 7: Global: Breast Cancer Liquid Biopsy Market: Breakup by Region (in %), 2023
  • Figure 8: Global: Breast Cancer Liquid Biopsy (Reagent Kits) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 9: Global: Breast Cancer Liquid Biopsy (Reagent Kits) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 10: Global: Breast Cancer Liquid Biopsy (Instruments) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 11: Global: Breast Cancer Liquid Biopsy (Instruments) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 12: Global: Breast Cancer Liquid Biopsy (Services) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 13: Global: Breast Cancer Liquid Biopsy (Services) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 14: Global: Breast Cancer Liquid Biopsy (Circulating Tumor Cells (CTCs)) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 15: Global: Breast Cancer Liquid Biopsy (Circulating Tumor Cells (CTCs)) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 16: Global: Breast Cancer Liquid Biopsy (Cell-Free DNA (cfDNA)) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 17: Global: Breast Cancer Liquid Biopsy (Cell-Free DNA (cfDNA)) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 18: Global: Breast Cancer Liquid Biopsy (Extracellular Vesicles (EVs)) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 19: Global: Breast Cancer Liquid Biopsy (Extracellular Vesicles (EVs)) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 20: Global: Breast Cancer Liquid Biopsy (Other Circulating Biomarkers) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 21: Global: Breast Cancer Liquid Biopsy (Other Circulating Biomarkers) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 22: Global: Breast Cancer Liquid Biopsy (Reference Laboratories) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 23: Global: Breast Cancer Liquid Biopsy (Reference Laboratories) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 24: Global: Breast Cancer Liquid Biopsy (Hospitals and Physician Laboratories) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 25: Global: Breast Cancer Liquid Biopsy (Hospitals and Physician Laboratories) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 26: Global: Breast Cancer Liquid Biopsy (Other End Users) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 27: Global: Breast Cancer Liquid Biopsy (Other End Users) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 28: North America: Breast Cancer Liquid Biopsy Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 29: North America: Breast Cancer Liquid Biopsy Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 30: United States: Breast Cancer Liquid Biopsy Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 31: United States: Breast Cancer Liquid Biopsy Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 32: Canada: Breast Cancer Liquid Biopsy Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 33: Canada: Breast Cancer Liquid Biopsy Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 34: Asia-Pacific: Breast Cancer Liquid Biopsy Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 35: Asia-Pacific: Breast Cancer Liquid Biopsy Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 36: China: Breast Cancer Liquid Biopsy Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 37: China: Breast Cancer Liquid Biopsy Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 38: Japan: Breast Cancer Liquid Biopsy Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 39: Japan: Breast Cancer Liquid Biopsy Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 40: India: Breast Cancer Liquid Biopsy Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 41: India: Breast Cancer Liquid Biopsy Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 42: South Korea: Breast Cancer Liquid Biopsy Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 43: South Korea: Breast Cancer Liquid Biopsy Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 44: Australia: Breast Cancer Liquid Biopsy Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 45: Australia: Breast Cancer Liquid Biopsy Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 46: Indonesia: Breast Cancer Liquid Biopsy Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 47: Indonesia: Breast Cancer Liquid Biopsy Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 48: Others: Breast Cancer Liquid Biopsy Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 49: Others: Breast Cancer Liquid Biopsy Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 50: Europe: Breast Cancer Liquid Biopsy Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 51: Europe: Breast Cancer Liquid Biopsy Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 52: Germany: Breast Cancer Liquid Biopsy Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 53: Germany: Breast Cancer Liquid Biopsy Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 54: France: Breast Cancer Liquid Biopsy Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 55: France: Breast Cancer Liquid Biopsy Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 56: United Kingdom: Breast Cancer Liquid Biopsy Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 57: United Kingdom: Breast Cancer Liquid Biopsy Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 58: Italy: Breast Cancer Liquid Biopsy Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 59: Italy: Breast Cancer Liquid Biopsy Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 60: Spain: Breast Cancer Liquid Biopsy Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 61: Spain: Breast Cancer Liquid Biopsy Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 62: Russia: Breast Cancer Liquid Biopsy Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 63: Russia: Breast Cancer Liquid Biopsy Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 64: Others: Breast Cancer Liquid Biopsy Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 65: Others: Breast Cancer Liquid Biopsy Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 66: Latin America: Breast Cancer Liquid Biopsy Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 67: Latin America: Breast Cancer Liquid Biopsy Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 68: Brazil: Breast Cancer Liquid Biopsy Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 69: Brazil: Breast Cancer Liquid Biopsy Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 70: Mexico: Breast Cancer Liquid Biopsy Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 71: Mexico: Breast Cancer Liquid Biopsy Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 72: Others: Breast Cancer Liquid Biopsy Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 73: Others: Breast Cancer Liquid Biopsy Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 74: Middle East and Africa: Breast Cancer Liquid Biopsy Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 75: Middle East and Africa: Breast Cancer Liquid Biopsy Market: Breakup by Country (in %), 2023
  • Figure 76: Middle East and Africa: Breast Cancer Liquid Biopsy Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 77: Global: Breast Cancer Liquid Biopsy Industry: SWOT Analysis
  • Figure 78: Global: Breast Cancer Liquid Biopsy Industry: Value Chain Analysis
  • Figure 79: Global: Breast Cancer Liquid Biopsy Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Breast Cancer Liquid Biopsy Market: Key Industry Highlights, 2023 and 2032
  • Table 2: Global: Breast Cancer Liquid Biopsy Market Forecast: Breakup by Product Services (in Million US$), 2024-2032
  • Table 3: Global: Breast Cancer Liquid Biopsy Market Forecast: Breakup by Circulating Biomarker (in Million US$), 2024-2032
  • Table 4: Global: Breast Cancer Liquid Biopsy Market Forecast: Breakup by End User (in Million US$), 2024-2032
  • Table 5: Global: Breast Cancer Liquid Biopsy Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 6: Global: Breast Cancer Liquid Biopsy Market: Competitive Structure
  • Table 7: Global: Breast Cancer Liquid Biopsy Market: Key Players
目次
Product Code: SR112024A6047

The global breast cancer liquid biopsy market size reached US$ 130.4 Million in 2023. Looking forward, IMARC Group expects the market to reach US$ 497.2 Million by 2032, exhibiting a growth rate (CAGR) of 15.5% during 2024-2032.

Breast cancer liquid biopsy refers to a non-invasive medical procedure that utilizes blood as a sample for the identification of tumor markers. It assists in evaluating the progression of breast cancer disease and detects Epidermal Growth Factor Receptor (EGFR) gene mutations that help clinicians in choosing the best course of action at the right time. Some of the common biomarkers that are used in this process include circulating tumor cells (CTC), extracellular vesicles, circulating tumor DNA, etc. Breast cancer liquid biopsy offers several benefits, including minimal invasiveness, characterization of new lesions, drug and therapeutic target identifications for cancer treatment, etc.

Breast Cancer Liquid Biopsy Market Trends:

The growing prevalence of breast cancer along with the escalating demand for non-invasive medical procedures is primarily driving the global breast cancer liquid biopsy market. In addition to this, the rising consumer awareness towards numerous benefits associated with the liquid biopsy technique, including quicker results, lower cost, minimal health risk, non-invasiveness, etc., is also augmenting the market growth. Moreover, various global organizations are conducting awareness campaigns to educate individuals about breast health and cancer diagnostic measures. This, in confluence with the increasing number of government and private reimbursement policies for breast cancer biopsy and other related medical procedures, is creating a positive outlook for the market. Apart from this, numerous manufacturers are making significant investments in the introduction of advanced biopsy techniques that enables the enhancement of several aspects of breast cancer management, such as prediction of prognosis, early diagnosis of relapse, serial sampling, efficient longitudinal monitoring of disease progress and response to treatment, etc. Furthermore, the emerging trend of personalized therapeutics coupled with the widespread adoption of polymerase chain reaction (PCR) and next-generation sequencing (NGS) for cancer detection will continue to drive the global breast cancer liquid biopsy market in the coming years.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global breast cancer liquid biopsy market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on product services, circulating biomarker and end user.

Breakup by Product Services:

Reagent Kits

Instruments

Services

Breakup by Circulating Biomarker:

Circulating Tumor Cells (CTCs)

Cell-Free DNA (cfDNA)

Extracellular Vesicles (EVs)

Others

Breakup by End User:

Reference Laboratories

Hospitals and Physician Laboratories

Others

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Biocept Inc., Bio-Rad Laboratories Inc., F. Hoffmann-La Roche AG, Fluxion Biosciences Inc., Guardant Health Inc., Illumina Inc., Menarini Silicon Biosystems (The Menarini Group), NeoGenomics Laboratories Inc., Qiagen and Sysmex Europe SE (Sysmex Corporation).

Key Questions Answered in This Report

  • 1. What was the size of the global breast cancer liquid biopsy market in 2023?
  • 2. What is the expected growth rate of the global breast cancer liquid biopsy market during 2024-2032?
  • 3. What has been the impact of COVID-19 on the global breast cancer liquid biopsy market?
  • 4. What are the key factors driving the global breast cancer liquid biopsy market?
  • 5. What is the breakup of the global breast cancer liquid biopsy market based on the product services?
  • 6. What are the key regions in the global breast cancer liquid biopsy market?
  • 7. Who are the key players/companies in the global breast cancer liquid biopsy market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Breast Cancer Liquid Biopsy Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Product Services

  • 6.1 Reagent Kits
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Instruments
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Services
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast

7 Market Breakup by Circulating Biomarker

  • 7.1 Circulating Tumor Cells (CTCs)
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Cell-Free DNA (cfDNA)
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Extracellular Vesicles (EVs)
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Others
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast

8 Market Breakup by End User

  • 8.1 Reference Laboratories
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Hospitals and Physician Laboratories
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Others
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Biocept Inc.
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
    • 14.3.2 Bio-Rad Laboratories Inc.
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
    • 14.3.3 F. Hoffmann-La Roche AG
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
    • 14.3.4 Fluxion Biosciences Inc.
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
    • 14.3.5 Guardant Health Inc.
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
    • 14.3.6 Illumina Inc.
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
    • 14.3.7 Menarini Silicon Biosystems (The Menarini Group)
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
    • 14.3.8 NeoGenomics Laboratories Inc.
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
    • 14.3.9 Qiagen
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
    • 14.3.10 Sysmex Europe SE (Sysmex Corporation)
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Product Portfolio